Arabic Arabic English English French French German German
dark

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic triple-negative breast cancer has advanced from Phase 1b to a Phase 2 trial. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

‘Wasfaty’ Service Activated in King Saud Medical City

Next Post

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

Related Posts
Total
0
Share